Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARVNNASDAQ:CAPRNASDAQ:SBBPNASDAQ:TYRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$7.39-2.4%$7.36$5.90▼$34.11$539.40M2.191.42 million shs1.13 million shsCAPRCapricor Therapeutics$11.78-15.5%$10.66$3.52▼$23.40$538.08M0.841.81 million shs3.08 million shsSBBPStrongbridge Biopharma$2.00$2.09$1.85▼$4.26$135.66M1.58866,464 shs684,684 shsTYRATyra Biosciences$10.43+1.0%$9.50$6.42▼$29.60$553.73M1.07316,339 shs425,189 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas-1.30%+9.39%+20.35%-10.20%-71.42%CAPRCapricor Therapeutics+6.09%+5.77%+90.96%+5.37%+175.49%SBBPStrongbridge Biopharma0.00%0.00%0.00%0.00%0.00%TYRATyra Biosciences+1.47%+1.57%+3.51%-10.17%-46.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARVNArvinas3.867 of 5 stars4.34.00.00.02.02.51.3CAPRCapricor Therapeutics2.2573 of 5 stars3.53.00.00.02.00.80.6SBBPStrongbridge BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ATYRATyra Biosciences2.0697 of 5 stars3.51.00.00.02.92.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARVNArvinas 2.55Moderate Buy$20.29174.55% UpsideCAPRCapricor Therapeutics 3.00Buy$35.50201.36% UpsideSBBPStrongbridge Biopharma 0.00N/AN/AN/ATYRATyra Biosciences 3.00Buy$30.83195.62% UpsideCurrent Analyst Ratings BreakdownLatest SBBP, TYRA, ARVN, and CAPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/13/2025CAPRCapricor TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$77.006/2/2025ARVNArvinasHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$24.006/2/2025ARVNArvinasLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$10.00 ➝ $9.006/1/2025ARVNArvinasLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/21/2025TYRATyra BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$33.005/20/2025CAPRCapricor TherapeuticsRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$31.005/15/2025ARVNArvinasUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$74.00 ➝ $21.005/14/2025CAPRCapricor TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$30.00 ➝ $30.005/9/2025ARVNArvinasMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$12.00 ➝ $11.005/5/2025ARVNArvinasCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $9.505/5/2025ARVNArvinasBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$20.00 ➝ $10.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARVNArvinas$426.90M1.26N/AN/A$8.17 per share0.90CAPRCapricor Therapeutics$17.36M30.99N/AN/A$0.73 per share16.14SBBPStrongbridge Biopharma$30.73M4.41N/AN/A$0.98 per share2.04TYRATyra BiosciencesN/AN/AN/AN/A$4.74 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARVNArvinas-$198.90M-$0.66N/AN/AN/A-75.51%-33.75%-16.75%7/29/2025 (Estimated)CAPRCapricor Therapeutics-$22.29M-$1.42N/AN/AN/A-146.86%-112.95%-57.00%8/6/2025 (Estimated)SBBPStrongbridge Biopharma-$45.08M-$0.78N/AN/AN/A-115.67%-66.82%-36.21%N/ATYRATyra Biosciences-$69.13M-$1.63N/AN/AN/AN/A-24.56%-23.31%8/6/2025 (Estimated)Latest SBBP, TYRA, ARVN, and CAPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025CAPRCapricor Therapeutics-$0.33-$0.53-$0.20-$0.53$3.16 million$2.73 million5/8/2025Q1 2025TYRATyra Biosciences-$0.49-$0.47+$0.02-$0.47N/AN/A5/1/2025Q1 2025ARVNArvinas-$0.93$1.14+$2.07$1.14$41.87 millionN/A3/27/2025Q4 2024TYRATyra Biosciences-$0.48-$0.43+$0.05-$0.43N/AN/A3/19/2025Q4 2024CAPRCapricor Therapeutics-$0.31-$0.16+$0.15-$0.16$9.87 million$11.13 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARVNArvinasN/AN/AN/AN/AN/ACAPRCapricor TherapeuticsN/AN/AN/AN/AN/ASBBPStrongbridge BiopharmaN/AN/AN/AN/AN/ATYRATyra BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARVNArvinasN/A4.644.64CAPRCapricor TherapeuticsN/A4.194.19SBBPStrongbridge Biopharma0.383.002.95TYRATyra BiosciencesN/A29.5529.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARVNArvinas95.19%CAPRCapricor Therapeutics21.68%SBBPStrongbridge Biopharma52.03%TYRATyra Biosciences84.14%Insider OwnershipCompanyInsider OwnershipARVNArvinas4.73%CAPRCapricor Therapeutics10.50%SBBPStrongbridge Biopharma5.10%TYRATyra Biosciences15.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARVNArvinas42072.99 million65.18 millionOptionableCAPRCapricor TherapeuticsN/A45.68 million40.01 millionOptionableSBBPStrongbridge Biopharma7267.83 millionN/AOptionableTYRATyra Biosciences2053.09 million42.81 millionOptionableSBBP, TYRA, ARVN, and CAPR HeadlinesRecent News About These CompaniesTyra Biosciences (NASDAQ:TYRA) Shares Up 7.1% - Time to Buy?June 10 at 11:57 AM | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Shares Gap Up - Time to Buy?June 9, 2025 | marketbeat.comTyra Biosciences, Inc. (NASDAQ:TYRA) Receives Average Rating of "Buy" from AnalystsJune 6, 2025 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Trading Down 6% - Here's What HappenedJune 5, 2025 | marketbeat.comTyra Biosciences, Inc. (NASDAQ:TYRA) Sees Significant Growth in Short InterestJune 4, 2025 | marketbeat.comTyra Biosciences, Inc. (NASDAQ:TYRA) Stake Trimmed by Canaan Partners XI LLCJune 3, 2025 | marketbeat.comMillennium Management LLC Increases Stock Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)May 31, 2025 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Trading 6.1% Higher - Here's WhyMay 30, 2025 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Now Covered by Piper SandlerMay 23, 2025 | marketbeat.comHC Wainwright Has Optimistic Outlook of TYRA FY2025 EarningsMay 23, 2025 | marketbeat.comEquities Analysts Offer Predictions for TYRA FY2026 EarningsMay 22, 2025 | marketbeat.comVestal Point Capital LP Makes New Investment in Tyra Biosciences, Inc. (NASDAQ:TYRA)May 21, 2025 | marketbeat.comDimensional Fund Advisors LP Increases Stock Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)May 19, 2025 | marketbeat.comJanus Henderson Group PLC Has $24.29 Million Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)May 18, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Purchases Shares of 244,245 Tyra Biosciences, Inc. (NASDAQ:TYRA)May 17, 2025 | marketbeat.comTyra Biosciences, Inc. (NASDAQ:TYRA) Shares Acquired by Orbimed Advisors LLCMay 15, 2025 | marketbeat.comCubist Systematic Strategies LLC Takes $1.53 Million Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)May 15, 2025 | marketbeat.comTyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Rating of "Buy" by BrokeragesMay 13, 2025 | marketbeat.comTyra Biosciences to Participate at Upcoming Investor ConferencesMay 12, 2025 | prnewswire.comOne Tyra Biosciences Insider Raised Stake By 284% In Previous YearMay 9, 2025 | finance.yahoo.comTyra Biosciences Reports First Quarter 2025 Financial Results and HighlightsMay 8, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSBBP, TYRA, ARVN, and CAPR Company DescriptionsArvinas NASDAQ:ARVN$7.39 -0.18 (-2.38%) Closing price 04:00 PM EasternExtended Trading$7.25 -0.14 (-1.95%) As of 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Capricor Therapeutics NASDAQ:CAPR$11.78 -2.16 (-15.49%) Closing price 04:00 PM EasternExtended Trading$11.88 +0.10 (+0.85%) As of 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. Strongbridge Biopharma NASDAQ:SBBPStrongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA.Tyra Biosciences NASDAQ:TYRA$10.43 +0.10 (+0.97%) Closing price 04:00 PM EasternExtended Trading$10.36 -0.07 (-0.67%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
